NCT02773576View on ClinicalTrials.gov

Safety and Tolerability of Risperidone Implants

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Schizophrenia
Interventions
DRUG

Risperidone implant

Trial Locations (1)

92845

Collaborative Neuroscience Network, Garden Grove

Sponsors
All Listed Sponsors
lead

Braeburn Pharmaceuticals

INDUSTRY

NCT02773576 - Safety and Tolerability of Risperidone Implants | Biotech Hunter | Biotech Hunter